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The clinical and economic impacts of monitoring cardiac function in patients given doxorubicin have yet to be determined,
especially in relation to patient age, cumulative doxorubicin dose, and the relative efﬁcacies of doxorubicin-based vs alternative
regimens. We developed a decision analysis model that includes these factors to estimate the incremental survival beneﬁt and
cost-effectiveness of using multiple gated acquisition scans to measure left-ventricular ejection fraction before and during
doxorubicin chemotherapy. Probability distributions for the incidences of abnormal left-ventricular ejection fraction ﬁndings
and congestive heart failure were derived from a retrospective review of 227 consecutive cases at The University of Michigan
Medical Center and published ﬁndings. Multiple gated acquisition-scan monitoring minimally improved the probability of 5-year
survival (51.5% in the base–case scenario). For patients who received up to 350 mg m
72 of doxorubicin, multiple gated
acquisition-scan screening had an incremental cost of $425402 per life saved for patients between the ages of 15–39. This
incremental cost markedly decreased to $138191, for patients between the ages of 40–59, and to $86829 for patients older
than 60 years. The small gain in 5-year survival probability secondary to multiple gated acquisition scan monitoring doubled for
all age groups when the average cumulative dose for doxorubicin reached 500 mg m
72. Variations in the cure rate differences
between the doxorubicin and alternative regimens had insigniﬁcant effects on the improvement in 5-year survival rates from
multiple gated acquisition-scan screening. The use of multiple gated acquisition scans for pretreatment screening appears to be
more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m
72 or less.
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Anthracyclines are common anticancer drugs that are active against a
variety of human tumours, and tumour response to them is often
dose dependent (Shan et al, 1996). Although effective, anthracyclines
are also cardiotoxic and can induce acute, subacute, or delayed cardi-
ac sideeffects (Steinherz and Yahalom, 1997). Irreversible subacute or
early-onset chronic progressive cardiotoxicity (Giantris et al, 1998)
are the most common forms of cardiotoxicity resulting from anthra-
cycline administration and depend on both the cumulative dose and
the administration rate (Von Hoff et al, 1979). Manifestation of these
types of cardiotoxicity usually occur within a year of completing
anthracycline therapy and produce mortality rates of up to 60%
(Shan et al, 1996; Steinherz and Yahalom, 1997; Giantris et al,
1998). If the risk of anthracycline-induced cardiotoxicity could be
accurately predicted, high-risk populations might be spared anthra-
cycline exposure and low-risk patients might accrue maximum
beneﬁt from adequate doses of anthracyclines.
Monitoring the left ventricular ejection fraction (LVEF) with
serial radionuclide ventriculography techniques such as multiple
gated acquisition (MUGA) scanning can be used to estimate the risk
of cardiotoxic reactions to anthracyclines (Stewart and Ratan,
1997). Schwartz et al (1987) reviewed clinical characteristics and
LVEF (measured by serial resting radionuclide angiography) in
1487 cancer patients who were monitored with MUGA scanning
during doxorubicin (Dox) chemotherapy. They identiﬁed patients
at high risk for subacute cardiotoxicity and used their ﬁndings to
propose guidelines for monitoring LVEF in patients undergoing
Dox chemotherapy (Schwartz et al, 1987). Those guidelines involve
a baseline LVEF measurement before the administration of
100 mg m
72 Dox. They also recommend subsequent measurements
after cumulative doses have been given as follows: If the baseline
LVEF is normal (450%), the next LVEF measurement is conducted
when the cumulative Dox dose reaches 250–300 mg m
72. Patients
with a history of heart disease, radiation therapy, abnormal electro-
cardiographic results, or cyclophosphamide exposure should
undergo a third LVEF measurement when the cumulative dose
reaches 400 mg m
72; patients without these risk factors should
undergo a third measurement when the cumulative dose reaches
450 mg m
72. LVEF measurement should be repeated before each
subsequent dose (i.e., those that exceed 400 mg m
72 for the former
group and 450 mg m
72 for the latter group). For all patients, if
LVEF declines by 10% or more, Dox treatment should be stopped.
If the baseline LVEF measurement is 30–50%, LVEF should be
measured before each dose is given, and Dox should be discontin-
ued if LVEF drops below 30%. If the baseline measurement is less
than 30%, Dox should not be given at all.
These guidelines have several limitations. First, they do not
account for the age of the patient, which is known to affect the risk
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not consider the contribution of Dox cumulative dose. The prob-
ability of Dox-induced cardiotoxicity has been shown to be
minimal for cumulative doses of 350 mg m
72 or less, especially
in patients less than 40 years old (Von Hoff et al, 1979). The total
cumulative Dox dose in several common anthracycline-based regi-
mens (e.g., Dox+cyclophosphamide (AC), Dox+bleomycin+
vinblastine+dacarbazine (ABVD), cyclophosphamide+Dox+vincris-
tine+prednisone (CHOP)) is approximately 350 mg m
72, and the
low probability of cardiotoxic reactions at this dose makes the
beneﬁt of pretreatment screening questionable for patients who
are less than 40 years old. Third, the Schwartz guidelines were
developed with a subset of 282 patients considered to be at high
risk of developing congestive heart failure (CHF); most (62%) of
these high-risk patients received Dox doses in excess of
450 mg m
72, whereas only 12% of the original group of 1487 were
given doses that high. Thus, the beneﬁt of MUGA-scan monitoring
seen in the high-risk study cohort might not be applicable to
patients who receive lower doses. In addition, the sensitivity and
positive predictive value of MUGA-scan screening for Dox doses
less than 100 mg m
72 in the Schwartz study were quite low
(22% and 14%, respectively) (Schwartz et al, 1987). Finally, the
proposed guidelines are demanding and compliance with them
has been poor; according to one report, ‘many centres perform
only a single LVEF measurement at an intermediate cumulative
dose’ (Carrio et al, 1996).
An additional consideration that has yet to be addressed is the
risk associated with using less-effective forms of therapy after a
false-positive MUGA scan result, especially at the initial screening
stage. Such a result might tend to favour the use of an alternative,
non-anthracycline-containing regimen with inferior antitumour
efﬁcacy. Thus, the risk of reducing the rates of cure of cancer or
response in the case of a false-positive MUGA scanning result
should be considered.
We believe that guidelines for monitoring cardiotoxic reactions
in patients given anthracycline chemotherapy should account for
patient age, cumulative Dox dose, and the risk that a false-positive
result may affect the choice of chemotherapy. To address these
issues, we developed a decision analysis model which includes these
factors and used that model to study the cost-effectiveness of
monitoring LVEF with MUGA scanning during doxorubicin
chemotherapy.
METHODS
Decision analysis model
We constructed a decision analysis model to assess the clinical
beneﬁt and cost-effectiveness of MUGA screening. All analyses were
produced with Treeplan software (Decision Support Services, San
Francisco, CA, USA). The base-case model was constructed for a
patient considering chemotherapy for Hodgkin’s lymphoma. The
total Dox dose was assumed to be 4350 mg m
72, which is
50 mg m
72 above the average total dose for six cycles of ABVD
chemotherapy. Three scenarios were analyzed to assess the effect
of age: one for patients aged 15–39 years, one for patients aged
40–59 years, and one for patients aged 60 years or older.
The decision-analytic model (Figure 1) begins with the decision
whether to perform a baseline (screening) MUGA scan before
chemotherapy. If a screening scan is performed, there are two
possible outcomes: negative or positive scan results. If the screening
MUGA scan is positive (i.e., the LVEF is less than 50%), intensive
monitoring will occur with a repeated scan before each dose, as
recommended by the guidelines. If the screening MUGA scan is
negative and Dox is given, CHF may occur, in mild, moderate,
or severe form. If a screening MUGA scan is not conducted, all
patients are assigned to Dox therapy. Again, after Dox therapy,
CHF may occur, with varying levels of severity.
Data and assumptions
We reviewed the records of 227 consecutive patients who had
MUGA-scan screening studies at The University of Michigan Medi-
cal Center between 1 July 1995 and 1 July 1996 to assess the
likelihood of having a positive (LVEF 550%) MUGA scan before
the start of Dox therapy.
For patients who underwent baseline MUGA-scan screening, we
determined the likelihood of CHF occurrence and severity based on
previously published studies. We assumed that the probability of
CHF after a positive MUGA scan to be zero, given the ﬁndings
of Schwartz et al (1987) that CHF was not found in any of the
patients with abnormal baseline LVEF whose care followed
Schwartz’s guidelines. Schwartz et al (1987) also observed a seven-
fold reduction in CHF incidence in patients whose care followed
their proposed guidelines compared with patients whose care did
not follow the guidelines. Therefore, for our model, we assumed
that the probability of CHF occurring in a patient whose screening
scan was negative was equal to the reported probability of CHF in
patients given the same Dox dose but no LVEF screening measure-
ment (Von Hoff et al, 1979), divided by seven. This calculation
maximized the beneﬁt of MUGA screening for this group.
For patients who did not undergo baseline MUGA-scan screen-
ing, we estimated the probabilities of CHF incidence and severity
from a previous report of patients given 350 mg m
72 of Dox on
a 3-week schedule who did not have LVEF measurements during
treatment (Von Hoff et al, 1979). The probability of cardiotoxicity
was adjusted by age using estimates from published data (Von Hoff
et al, 1979).
Clinical outcomes
We used 5-year survival as our clinical outcome measure. Several
studies have shown that adding doxorubicin to the chemotherapy
regimen for the treatment of Hodgkin’s disease improves survival
(Bonadonna et al, 1986; Radford et al, 1995). We incorporated
published cancer survival rates for patients with Hodgkin’s disease
treated with chemotherapy that either included or did not include
Dox from the study by Bonadonna et al (1986). According to these
data, treatment with MOPP–ABVD, which includes Dox,
produced a 76% 5-year disease-free survival rate, whereas treat-
ment with MOPP, which does not include Dox, produced a 62%
5-year disease-free survival rate (Bonadonna et al, 1986).
To determine 5-year survival rates from CHF, we used data
from a published meta-analysis (Dracup et al, 1994). We assumed
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Figure 1 Decision analysis tree for evaluating the effects of MUGA scan
monitoring on 5-year survival probability for patients who are treated with
doxorubicin based chemotherapy.
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Schwartz et al, 1987) corresponded to the New York Heart Associa-
tion classes II, III, and IV, respectively, for use in our model. The
5-year mortality ranges associated with mild, moderate, and severe
CHF are 25–50%, 50–100%, and 100%, respectively. Because the
use of angiotensin-converting enzyme inhibitors has increased CHF
survival rates (Kleber and Niemoller, 1993), we used the lower
bounds of the mortality ranges to estimate CHF 5-year survival
rates of 75%, 50%, and 0% (Dracup et al, 1994), (Table 1).
Death rates from causes other than Hodgkin’s disease and
cardiotoxicity were derived from data published by Bennett et al
(1993). In that study these death rates from causes other than
Hodgkin’s lymphoma or cardiovascular causes were reported as
6, 11, and 26% for patients aged 540, 40–59, and 460 respec-
tively. The 5-year survival probability for all outcomes were
multiplied by the survival probability from death by causes other
than Hodgkin’s lymphoma and CHF.
The survival rates for cancer and CHF are assumed to be inde-
pendent, i.e., the probability of survival in each outcome category
listed below is the product of the probability of cancer-speciﬁc
survival multiplied by the probability of survival from CHF and
the probability of death from other causes. If the decision is made
to treat with a ‘no-Dox’ regimen, then the risk for developing
treatment-related cardiotoxicity is assumed to be zero.
The outcome calculations were calculated as follows and the
results are shown in Table 1: Patients with a positive (abnormal)
screening LVEF result with Dox therapy and CHF: The probability
distribution was considered to be zero, given the ﬁndings of
Schwartz et al (1987) that CHF was not found in any of the
patients with abnormal baseline LVEF whose care followed
Schwartz’s guidelines.
For patients with a positive (abnormal) screening result with
Dox therapy without CHF: Survival was assumed to equal the
probability of survival from cancer on a Dox-containing regimen
multiplied by the survival probability from death by causes other
than Hodgkin’s lymphoma and CHF.
For patients with a negative (normal) screening result with Dox
therapy with CHF: The probability of survival for each degree of
CHF was estimated by multiplying the probability of survival from
CHF by the probability of survival from cancer after ‘no-Dox’
chemotherapy (62%) and by the survival probability from death by
causes other than Hodgkin’s lymphoma and CHF. This group of
patients has higher 5-year cancer relapse rates compared to a group
receiving Dox therapy by approximately 27% (Bonadonna et al,
1986).This estimate wasbased onthe assumption that baseline moni-
toring would predict the development of CHF early in treatment and
prompts a rapid change to a ‘no-Dox’ chemotherapy regimen.
For patients with a negative (normal) LVEF result with Dox
therapy without CHF: Survival was equal to the probability of
survival from cancer after Dox-containing chemotherapy (76%)
multiplied by the survival probability from death by causes other
than Hodgkin’s lymphoma and CHF.
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Table 1 Probabilities used for and outcomes generated by the decision analysis model
Variable Probability Reference
Positive MUGA scan result Primary data,
Patients 540 years 0.02* Univ. Michigan
Patients 40–59 years 0.01
Patients 459 years 0.02
CHF after Dox without MUGA scan (dose 5350 mg m
72) Von Hoff et al, 1979
Patients 540 years 0.008
Patients 40–59 years 0.023
Patients 459 years 0.036
CHF without MUGA scan Von Hoff et al, 1979
Mild 0.35
Moderate 0.09
Severe 0.56
CHF with MUGA scan Schwartz et al, 1987
Mild 1.00
Moderate 0.00
Severe 0.00
5-year survival for patients with Hodgkin’s lymphoma
Treated with MOPP 0.62 Bonadonna et al, 1986
Treated with MOPP-ABVD 0.76
5-year survival from CHF Dracup et al, 1994
Mild 0.75 Kleber and Niemoller, 1993
Moderate 0.50
Severe 0.00
5-year survival from causes other than Hodgkin’s lymphoma and CHF Bennett et al, 1993
Patients 540 years 0.94
Patients 40–59 years 0.89
Patients 459 years 0.74
Predicted outcomes (base model, age 15–39 years) Probabilities of 5-year survival
Positive MUGA scan, intensive monitoring during chemotherapy 0.71
Negative MUGA, CHF develops during chemotherapy 0.44
Negative MUGA, no CHF develops during chemotherapy 0.71
No MUGA monitoring, severe CHF develops during chemotherapy 0.00
No MUGA monitoring, moderate CHF develops during chemotherapy 0.36
No MUGA monitoring, mild CHF develops during chemotherapy 0.54
No MUGA monitoring, no CHF develops during chemotherapy 0.71
MUGA=multiple gated acquisition; CHF=congestive heart failure; Dox=doxorubicin. *False positive (LVEF increased to 67% after
225 mg m
72 of doxorubicin).
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CHF: The probability of survival for each degree of CHF was esti-
mated by multiplying the probability of survival from CHF by the
probability of survival from cancer after Dox-containing chemother-
apy and by the survival probability from death by causes other than
Hodgkin’s lymphoma and CHF. It was assumed that CHF detection
would be delayed by the lack of monitoring and therefore a total
Dox dose of 350 mg m
72 would be administered.
Cost estimates
We calculated the economic costs associated with the clinical strate-
gies of pretreatment MUGA-scan screening and no pretreatment
screening. The cost of the MUGA scan itself was $751, the charge-
list price at The University of Michigan Medical Center in 1996.
Costs in terms of patient time were calculated by multiplying an
estimated 3 h (for travel, waiting, and testing) by the average hourly
earnings for each age group from a previously published population
survey (Stinnett et al, 1996). The average hourly earnings were
converted from 1993 dollars into 1996 dollars by using annual
consumer price indices for health care expenditures. Annual costs
for CHF-related care were based on a previously published cost-
effectiveness analysis of pharmacological treatments for CHF:
$8117 per patient per 10 years (Paul et al, 1994). Paul et al (1994)
determined that the 10-year expected costs of CHF treatment using
standard plus enalapril therapy is $8117 in 1992 dollars using a 5%
discount rate. For our model, we needed to determine the expected
costs of CHF treatment for a 5-year period in 1996 dollars using a
3% discount rate. A discount rate of 3% is currently the accepted
discount rate, as given by a recent report of the U.S. Panel on
Cost-Effectiveness in Health and Medicine (Gold et al, 1996). We
‘backed into’ an estimate of the annual cost of CHF therapy by
assuming a constant annual survival rate over the 10-year period.
We then converted the annual cost of CHF therapy in 1992 dollars
into 1996 dollars by using annual consumer price indices for health
care expenditures. Once again, we invoked the assumption of a
constant annual survival rate and used a 3% discount rate to deter-
mine the total costs of CHF therapy for a 5-year period, as required
by our model. The 5-year cost for CHF treatment was $6885. The
costs of Dox-based and non-Dox-based chemotherapy were
assumed to be equal except for patients who received ‘no-Dox’
chemotherapy regimen who have a higher relapse rate by an
approximately 27% (Bonadonna et al, 1986). The cost for additional
high dose salvage chemotherapy for the group was calculated by
multiplying the number of excess cases requiring salvage chemother-
apy by the cost of high dose salvage chemotherapy ($45792) (Smith
et al, 1997). Because only patients with good performance status are
generally given chemotherapy, charges for caregiver time were not
included in the cost calculation.
Cost-effectiveness calculations
We calculated the incremental cost-effectiveness ratio (ICER) for
MUGA-scan monitoring as compared to no monitoring as follows:
ICER   test cost  patient ÿ time cost  cost of additional
salvage chemotherapy casesÿ 5-year cost of CHF6
reduction in CHF incidence=Number of lives saved at 5 years:
Sensitivity analysis
Sensitivity analyses were used to assess the effects of cumulative dose
and cure rates from Dox and non-Dox regimens on the outcomes of
the model. Dox cumulative dose is an important predicator of the
risk of cardiotoxicity and the risk increases markedly for doses of
500 mg m
72 and higher (Von Hoff et al, 1979). To assess the effect
of higher cumulative doses on model outcome, we increased the
average cumulative dose to 500 mg m
72 for the group that had
no pretreatment screening but maintained the dose at an average
of 350 mg m
72 for the monitored group. These choices were made
on the basis of ﬁndings by Schwartz et al (1987) that the average
cumulative dose for the group cared for according to the proposed
guidelines was 348 mg m
72 and that for the patients whose care did
not follow the guidelines the average cumulative dose was
512 mg m
72. This difference could have been due to a delay in
detection of CHF in the second group that allowed them to receive
a higher cumulative dose. To assess the effects of possible differences
in cure rates between Dox and non-Dox regimens on model
outcome, we varied in the model the overall cancer speciﬁc survival
and the difference in cancer-speciﬁc survival between the Dox and
non-Dox regimens. In one group of these analyses the overall cancer
speciﬁc survival was assumed to be above 50% (typical rates for
lymphomas), and the second group the cancer speciﬁc survival
was assumed to be less than 50% (typical rates for leukaemia and
sarcomas). We then varied the difference in cancer speciﬁc survival
between the two regimens at 10–40% for overall cure rates below
50% and 10–70% for cure rates above 50%.
RESULTS
Frequency of positive screening MUGA scan by age groups
Of the 227 patients screened from The University of Michigan
database, 47 patients (21%) were 15–39 years old; 98 (43%) were
40–59 years old; and 82 (36%) were 60 years or older. The screen-
ing MUGA scan was abnormal in only four cases (2%) – 2% (one
out of 47 cases) in the youngest age group, 1% (one out of 98
cases) in the 40–59-year-old group, and 2% (two out of 82 cases)
in the older than 60-year-old group. The one positive screening
MUGA scan in patients who were less than 40 years old prompted
a monitoring with serial MUGA scan (one scan after each dose).
The positive screening scan is likely to have been a false-positive
ﬁnding because the patient’s LVEF increased to 67% after a cumu-
lative Dox dose of 228 mg m
72.
Cost-effectiveness by age
Results from the base–case, in which patients were given an aver-
age Dox dose of 350 mg m
72, are shown in Figures 2 and 3.
Pretreatment MUGA scanning increased 5-year survival probabil-
ities very modestly; the incremental improvement in survival
rates were less than 1.5% for all three of the age groups. Patients
younger than 40 years had the lowest improvement in their 5-year
survival rates, approximately 50.4%, as shown in Figure 2. Cost-
effectiveness was also dependent on age. Patients younger than 40
years old had the highest cost-effectiveness ratio ($425402 per life
saved, as shown in Figure 3). The incremental cost-effectiveness
ratio dropped signiﬁcantly for patients in the 40–59 age group
($138191 per life saved), and for patients who were older than
60 years to $86829 per life saved.
Clinical outcome for MUGA scan monitoring and
cumulative dose
The improvement in 5-year survival rates because of MUGA scan
monitoring improved as the cumulative dose of Dox increased
(Figure 2). For an average cumulative dose of 500 mg m
72, the
small increments in 5-year survival probability because of
MUGA-scan screening doubled for all age groups. The incremental
improvement in 5-year survival probability reached 0.77% for
patients between the ages of 15–39, 2.12% for patients between
the ages of 40–59, and 2.7% for patients older than 60 years.
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In contrast to age and cumulative dose, the differences in 5-year
cure rates between Dox and an alternative chemotherapy regimen
had very little effect on the clinical beneﬁt from MUGA-scan
monitoring (Figure 4A,B). The overall cure rates from chemother-
apy can vary signiﬁcantly. For example, 5-year survival rates above
50% are common in Hodgkin’s lymphoma (Bonadonna et al,
1986), while the expected cure rates for acute myeloid leukaemia
are below 50% (Estey et al, 1997). We have examined two scenarios
with our sensitivity analyses using a model for a cumulative Dox
dose of 5350 mg m
72. In the ﬁrst case scenario the overall survi-
val rate was ﬁxed for the Dox regimen at 76% as in the base-case
model while the rates for the alternative regimen were decreased by
10% for each subsequent analysis (Figure 4A). The 5-year survival
beneﬁt from MUGA scanning had minimal variation for all tested
levels for all age groups (Figure 4A). In the second case scenario we
assumed that the 5-year survival rate for the Dox regimen was 46%
and we decreased the 5-year survival rates for the alternative regi-
men by 10% for each tested level. Again, there was minimal
variation in the modest clinical beneﬁt from MUGA scan monitor-
ing for all age groups (Figure 4B).
DISCUSSION
Our cost-effectiveness analysis conﬁrmed that factors such as
patient age and cumulative Dox dose inﬂuence the utility of
MUGA-scan monitoring in patients given Dox chemotherapy.
The decision analyses showed that age signiﬁcantly affects the
potential beneﬁt of pretreatment MUGA-scan screening, with older
patients beneﬁting the most. Our cohort included a signiﬁcant
proportion of young patients (21% were less than 40-years-old),
as might be expected for a tertiary referral center; nevertheless,
the single abnormal LVEF result in this subgroup turned out to
be a false-positive ﬁnding. Even if we assumed that the false-posi-
tive scan was truly positive (as we did in this cost-effectiveness
analysis), the overall improvement in 5-year survival probability
was very small (less than 0.4%), and the cost-effectiveness ratio
for MUGA scan monitoring for cumulative Dox dose of
5350 mg m
72 for patients in this age range was much higher than
in other age groups ($425402 vs $138191 vs $86829 per life
saved).
We recognize that assigning an economic value for survival
improvement is difﬁcult regardless of how small the differences
in clinical beneﬁt are. However, to put these results in perspective,
we can compare these results to accepted measures to improve
survival for patients with cancer. For example, patients with stage
III colon cancer can expect their 5-year survival to improve by
approximately 18% with adjuvant chemotherapy (Mamounas et
al, 1999). Based on recently published data for an adjuvant
chemotherapy cost analysis (Michel et al, 1999), the expected cost
for adjuvant chemotherapy would be $5485 per patient and the
expected cost per life saved at 5 years would be $30472. We have
found using our model that the cost per life saved at 5 years for
patients who are younger than 40 years old and received Dox at
a cumulative dose of 4350 mg m
72 is $425402 which is 14 times
higher than the cost for adjuvant chemotherapy for stage III colon
cancer. In contrast, patients who were older than 60 years had a
relative cost for MUGA scanning that is 2.85 times higher than
the cost for adjuvant chemotherapy for stage III colon cancer.
Cumulative Dox dose was also a strong determinant of the clin-
ical beneﬁt of MUGA-scan screening, with most of the beneﬁt
associated with doses higher than 350 mg m
72. When the small
survival beneﬁt associated with monitoring was compared between
two cumulative Dox doses, the survival beneﬁt conferred by
MUGA scanning was twice as high for the 500 mg m
72 group as
for the 350 mg m
72 group. Furthermore, the effects of age and
cumulative dose seemed to be additive, which further emphasized
that patients who are younger than 40 and are given
4350 mg m
72 of Dox are the least likely to beneﬁt from pretreat-
ment MUGA scanning. All of these ﬁndings agree with those of
Von Hoff et al (1979) on risk factors for Dox-induced CHF.
We observed very little impact for the difference in the 5-year
survival rates between the Dox chemotherapy regimen and an alter-
native regimen on the clinical beneﬁt from monitoring with
MUGA scan. Our inability to detect these effects might have
resulted from the very small overall beneﬁt of MUGA scan. An
additional factor one might also consider is that the model we used
was biased in favour of maximizing the beneﬁt of MUGA-scan
monitoring through its assumption that Schwartz’s ﬁndings with
high-risk patients (Schwartz et al, 1987) could be generalized to
all patients at all dose levels.
Our study has limitations that are typical of decision analysis
studies, and our ﬁndings should be interpreted in light of these
limitations. First, the probability distributions for the results of
MUGA-scan screening were derived from retrospective data. Also,
patients who are at risk for cardiotoxicity because of a history of
coronary artery disease or CHF probably would not have been
given Dox-based chemotherapy, and thus our ﬁndings may not
be applicable to patients with pre-existing cardiac problems. We
focused on subacute cardiotoxicity that develops within 12 months
after the end of Dox therapy; the data used for the outcomes in the
decision analysis models came from a study in which patients were
followed for a mean of 14 months (Schwartz et al, 1987). Unfortu-
nately, the cardiotoxic effects of anthracyclines can appear years or
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scan monitoring for detecting this type of delayed cardiotoxicity is
very low (Shan et al, 1996). Thus, more sensitive screening meth-
ods are being sought.
Despite these limitations, we believe that our ﬁndings will be
useful for improving the current guidelines for MUGA-scan screen-
ing. We believe that monitoring guidelines should account for
patient age and cumulative anthracycline dose; our ﬁndings also
highlight, for the ﬁrst time, the overall small contribution of
MUGA-scan monitoring to patient outcome, especially for Dox
doses of 350 mg m
72 or less in young patients. We recognize that
conducting prospective randomized studies in this area would be
extremely difﬁcult, and thus we used cost-effectiveness analyses
to investigate the inﬂuence of these factors.
In summary, we demonstrated that the cost-effectiveness of
using MUGA scans for monitoring anthracycline-induced cardio-
toxicity depends on patient age and cumulative drug dose. Our
ﬁndings suggest that the use of MUGA scanning for pretreatment
screening of patients who are younger than 40 years, have no
evidence of cardiac disease, and are given Dox at doses of
350 mg m
72 or less comes at a very high cost and has very mini-
mal beneﬁt for these patients. Future studies are needed to conﬁrm
these ﬁndings and to investigate the sensitivity, speciﬁcity, and
positive and negative predictive value of MUGA scan monitoring
for subacute and delayed anthracycline-induced cardiotoxicity.
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Figure 4 The beneﬁt of MUGA scan monitoring in improving 5-year survival rates, with a cumulative doxorubicin (Dox) dose of 4350 mg m
72, in terms
of different 5-year disease-free survival (DFS) rates for Dox vs non-Dox therapy. (A) A cost-effectiveness model was used in which the response rates for
the Dox regimen was maintained at 76% and the response for the alternative non-Dox regimen was dropped in decrements of 10%. (B) A cost-effective-
ness model was used in which the response rate for the Dox regimen was maintained at 46% and the response for the alternative regimen was dropped in
decrements of 10%.
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